objectives Imported Chagas disease (CD) is an emerging health problem in Europe due to immigration from endemic countries. Although WHO currently recommends two different serological methods to establish diagnosis, new tools like the ARCHITECT Chagas assay have potential for use as a single diagnostic test. Our objective was to determine an optimal signal-to-cut-off (S/CO) value for the ARCHITECT Chagas assay to diagnose CD with a single test.
Introduction
Chagas disease, also known as American trypanosomiasis, is endemic in 21 Latin American countries, and around 6 million people are chronically infected [1] . As a result of immigration from Latin America, imported Chagas disease is increasingly recognised as an emerging problem in Spain and other European countries [2, 3] . This anthropozoonosis is caused by Trypanosoma cruzi, a flagellate protozoan parasite in the blood. Vector-borne transmission is the main mode of infection in humans. When the triatomine vector bites the host, the parasite in the infective stage is transmitted in the faeces, penetrating the skin when the host rubs or scratches the bite. Other routes of transmission in humans include non-vectorborne transmission, such as vertical transmission, blood transfusion, organ transplantation and, as has recently been documented, oral transmission [4, 5] . The acute phase is rarely symptomatic, but becomes a lifelong infection if left untreated. Those infected may enter a prolonged second chronic phase, which may also be asymptomatic (chronic indeterminate phase) or develop symptoms of cardiac and/or gastrointestinal disease. The infection is frequently acquired during childhood, so that, based on the natural course of the disease, most Latin American immigrants living in Spain would now be in the chronic phase of the disease, at an age when the first signs and symptoms of cardiac and gastrointestinal involvement would be expected to appear [6, 7] . As parasitaemia is unusual during the chronic phase, direct parasitological methods used in the acute phase are usually negative, and PCR techniques show variable sensitivity (50-70%) [8] . In the chronic phase of the disease, therefore, indirect tests based on serum antibody detection are the best tools for performing an accurate diagnosis [9] . Following WHO recommendations, at least two positive serological tests based on different principles and antigens are needed to confirm the diagnosis [10] . A third test is performed when discordant results are obtained. Serological discrepancies are not uncommon, especially when using crude antigen-based serologies and in countries where Leishmania spp. is endemic [11] [12] [13] . To date, none of the existing serological techniques have proved sufficiently specific and sensitive to be recommended as a single test for the screening of the disease. New immunoassays using recombinant antigens [14] [15] [16] show better sensitivity and specificity than crude antigen tests, with commercially available enzyme-linked immunosorbent assays (ELISA) showing the best results. An expert committee from WHO and some guidelines recommend a single ELISA test for screening blood donors, and a review of evidence suggests that a single ELISA test may be sufficient for infection screening, with serological confirmation only needed in the event of a positive result [8] .
The fully automated platform ARCHITECT Chagas assay (Abbott Laboratories Wiesbaden, Germany) shows 100% sensitivity and 96.6% specificity [17, 18] and may therefore have potential for use as a single diagnostic test for chronic Chagas disease.
The objective of this study was to define the optimal cutoff value (S/CO) for use of the ARCHITECT Chagas assay as a single test for the diagnosis of chronic Chagas disease in the routine screening of immigrants from endemic regions.
Methods

Study design and participants
This retrospective observational study was performed in the Parasitology Department of the 12 de Octubre University Hospital (Madrid, Spain). All patients attending the 12 de Octubre University Hospital or associated primary care centres with requests for T. cruzi antibody detection between January 2014 and August 2017 were consecutively included in the study. Demographical data were collected and recorded retrospectively from the patients' records.
Diagnostic tests
The ARCHITECT Chagas assay was used to test all samples accompanied by a request for screening for T. cruzi infection. The results of the chemiluminescent reaction were measured in relative light units (RLUs) and expressed as sample RLUs/cut-off value (S/CO). Results were interpreted in accordance with the manufacturer's instructions as follows: positive (S/CO ≥ 1.00); grey zone (S/CO between 0.8 and 0.99); and negative result (S/CO < 0.8). Samples with S/CO values above 0.8 were also tested with an immunochromatographic test (ICT) (Bio Line, Standard Diagnostics) to confirm the result. If the results of the two tests were discordant, the sample was sent to the reference laboratory (National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Spain) where an indirect immunofluorescence antibody test (IFAT) was performed. IFAT titres equal to or above 1:40 were considered positive. When the sample volume was insufficient for all serological tests, a second sample was requested.
Classification of patients
• Patients without infection: Patients with a negative ARCHITECT Chagas result OR patients with at least two negative results in two different serological tests [8] .
• Confirmed cases of Chagas disease: Patients with at least two different positive serological tests [10] .
• Non-evaluable patients: Patients whose results were in the grey zone or indeterminate in two or more serological tests OR patients with discordant results in two different tests and an indeterminate or not performed third test. In these cases, a second sample was requested and re-evaluated with the diagnostic algorithm described above. These patients were reclassified according to the results of the second sample, when available.
Statistical analysis
Non-evaluable patients were excluded from the analysis. Receiver operating characteristic (ROC) curves were performed to establish the S/CO value using the ARCHI-TECT Chagas system that yielded the highest specificity and positive predictive value. Sensitivity and negative predictive values for this S/CO value were also calculated. Positive and negative predictive values and confidence intervals (CIs) were estimated for different prevalences using the bootstrapping technique, simulating 1000 samples with 348 subjects, as in the sample. Data analysis was performed using SPSS software, version 22.0, for Windows, (SPSS, Inc. Chicago, IL), ROC analysis macros and Diagnostic Tests computer program for SPSS [19, 20] . A diagnostic algorithm using the above S/CO value for ARCHITECT Chagas was constructed and a cost analysis performed comparing the proposed algorithm with the standard routine diagnosis.
Ethical aspects
The Clinical Research Ethics Committee of Hospital Universitario 12 de Octubre in Madrid, Spain, approved this study. The written consent of patients was not required because patients' records were reviewed retrospectively.
Results
Results are reported according to the STARD checklist (Supporting information S1). A total of 4153 samples were analysed in the ARCHITECT Chagas assay, 361 of which gave a reactive result (8.69%). Of these, 261 were women (72.3%). The median age at diagnosis was 38 years (2-79). A total of 335 were from Bolivia (92.8%). Trypanosoma cruzi serology was requested by primary care centres in 201 cases (55.7%) and by the gynaecology service in 93 cases (25.8%). All patients were diagnosed at the chronic phase of the disease.
Of the 361 reactive samples, 348 had S/CO values >1.0, and 13 were between 0.8 and 0.99. Sixty-six (18%) samples were initially discordant (positive/grey zone ARCHITECT and negative/indeterminate ICT): 59/66 of discrepancies were resolved with IFAT (11 confirmed cases and 48 non-infected patients), and the remaining seven were initially classified as not evaluable. After a second sample was requested, 1 of the initially not evaluable patients was classified as a confirmed case, four were non-infected and two remained non-evaluable (one remained serodiscordant, and no sample was sent in the other) (Figure 1) .
Hence, of the 361 reactive samples with ARCHITECT Chagas, 307 were finally confirmed as cases of T. cruzi infection (85.0%), 52 (14.4%) were non-infected, and two samples (0.6%) were non-evaluable. The seroprevalence of T. cruzi infection, therefore, was 7.39% (307/ 4153). Figure 2 shows S/CO values on the ARCHITECT Chagas according to the patient classification. A cut-off value of 3.80 yielded the highest specificity (100%; 95% confidence interval [CI], 0.93-1.00) and positive predictive value (100%; 95% CI: 0.99-1.00) (Figure 3) . The diagnostic accuracy of this proposed cut-off value is shown in Table 1 . Positive and negative predictive values for different prevalences are shown in Table 2 . Figure 4 represents the proposed diagnostic algorithm for the screening of Chagas disease in Latin American immigrants. Based on our algorithm, only 75 patients would have required additional serological testing with ICT, which would have saved 79.1% of immunochromatographic tests performed.
Discussion
Trypanosoma cruzi infection remains a public health problem in endemic countries and now also in nonendemic countries, due to immigration. Spain is one of the European countries that receive most immigrants from Latin America, with over 1 500 000 from countries where Chagas disease is endemic. Some 87 000 of these immigrants are estimated to be potentially infected with T. cruzi [21] , which means that screening this population could provide a clue to treating and preventing cardiac and digestive complications and avoiding congenital transmission [22, 23] . Spanish studies have recorded the seroprevalence of Chagas disease among Latin American immigrants as ranging from 2.5% to 22.3% [24] [25] [26] , while our study obtained a seroprevalence of 7.39%. Compared with other European countries, our seroprevalence was not as high as previously reported [27] . The wide range of seroprevalence reflects the heterogeneity of the population as determined by the geographical area, diagnostic test performed and study design.
The current diagnostic algorithm for chronic Chagas disease is based on WHO recommendations made fifteen years ago [10] . Conventionally, two positive results with different serological tests are required to confirm diagnosis, and discordant results are one of the problems faced by clinicians in routine clinical practice, especially in areas where Leishmania spp. is co-endemic with Chagas disease. In comparison with other studies, our initial discordant results were high (18%), although, following WHO guidelines, most were subsequently resolved with a third serological test or a second sample [26, 28] .
Many serological techniques have been developed for the detection of specific T. cruzi antibodies. Crude antigen-based tests, including the indirect hemagglutination assay (IHA), the immunofluorescent antibody assay (IFA) and enzyme-linked immunoabsorbent assays (ELISA), have been widely used in the past. As expected, these tests lacked specificity due to frequent cross-reactions with related protozoa, such as Leishmania spp. and Trypanosoma rangeli [12, 13] . The development of techniques using recombinant antigens [14, 16] and, more recently, chimeric recombinant antigens [15] , has helped to overcome the previous problem of specificity, as well as to improve the sensitivity of the serological tests. ARCHITECT Chagas is an automated chemiluminescent microparticle immunoassay based on four chimeric recombinant antigens (FP3, FP6, FP10 and TcF) for the detection of IgG antibodies to T. cruzi [17] . High sensitivity and specificity have been described for this automated assay [18] . This diagnostic platform also offers great potential due to the quantitative values of the results and the possibility of establishing different cut-offs depending on the purpose of the test. For these reasons, we propose a new algorithm to confirm infection with a single sample and a single test. Under the proposed strategy, therefore, only patients with a result of S/ CO < 3.80 on the ARCHITECT Chagas would require confirmation with a second serological technique. This approach simplifies routine diagnosis of infection and also reduces costs in the laboratory. As many as 284/307 (92.5%) confirmed chronic Chagas disease patients Indirect immunofluorescence assay. *Initially not evaluable patients: A second sample was requested and re-evaluated. Reclassification was performed on the basis of these results.
would not have required a second confirmatory serological test. Based on a conservative estimate of cases of Chagas disease in adult immigrants from endemic areas currently living in Spain (42 173 total estimated cases) [29] , this strategy could have saved 39 013 tests.
Other authors from a different Spanish region proposed a similar algorithm with a slightly higher S/CO, but fewer reactive samples [18] . A multicenter study would be useful to unify these results.
The main limitation of this study is that it was not possible to evaluate cross-reactivity of the ARCHITECT Chagas assay with other serological tests due to the retrospective nature of the study and serology for other infections, especially Leishmania spp., was not requested for most patients. For this reason, our cut-off value should be used in immigrants without clinical suspicion of leishmaniasis, which, fortunately, has quite different signs and symptoms from chronic Chagas disease. In addition to this, as in other studies carried out in our country, most of our patients were Bolivian immigrants; hence, our findings might only be useful in this type of population. Genetical diversity of the parasite should also be studied to prove if there are variations in the diagnostic accuracy of our proposed algorithm. A recent study from our country performed in a very similar population (i.e. Latin American immigrants, mostly Bolivians) has proved that there is no correlation between serological titres and the different discrete typing units (DTUs) of the parasite [30] ; therefore, no differences should be expected with our proposed cut-off. More studies in immigrants from other countries as well as in patients living in endemic areas should be done to validate our algorithm and to better assess the implications of the different DTUs in the serological diagnosis of Chagas Disease. Another limitation could be that rapid diagnostic tests (RDT) are reported to be less useful for screening, but sensitivity and specificity levels comparable to ELISA, IFA and IHA have been described for several RDTs [31, 32] . In fact, some authors recommend performing two different RDTs to confirm the diagnosis in areas with limited resources [33] . Adding their simplicity to use, the low-cost per test, and the quick delivery of results we believe these RDTs, and specifically ICTs, are a reliable confirmation diagnostic tool. Using it as our algorithm proposal, a false-negative result would always be detected by IFAT.
In conclusion, the proposed cut-off of 3.80 for the ARCHITECT Chagas assay shows enough specificity to be used as a single diagnostic test, above that value, for chronic Chagas disease among Bolivian immigrants. S/ CO values on ARCHITECT Chagas that are between 0.80 and 3.80 should be confirmed with a different diagnostic test or by repeating the test on another sample. Prospective studies to validate this algorithm in a larger cohort of patients should also be carried out.
